Conducting Phase II/III study of rhGM-CSF in patients with novel coronavirus infection (COVID-19).
- Funded by Japan Agency for Medical Research and Development (AMED)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Funder
Japan Agency for Medical Research and Development (AMED)Principal Investigator
COO. Shigeki SHIMASAKIResearch Location
JapanLead Research Institution
Research & Development, Nobelpharma Co Ltd.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 2 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified